Persberichten

San Ramon, CA, USA – October 5, 2020 – BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that Chris Wolff has been named Vice President of U.S. Sales. In this role, Mr. Wolff will be responsible for driving enrollment in the ongoing ALIVE Trial studying the Company’s Revivent TC™ Transcatheter Ventricular Enhancement System, which has reimbursement from the Centers for Medicare and Medicaid Services (CMS).


 

San Ramon, Calif. – September 2, 2020BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that the Company has resumed cases in the pivotal ALIVE Trial studying Less Invasive Ventricular Enhancement, or LIVE™ Therapy, using the Revivent TC™ Transcatheter Ventricular Enhancement System.


REVIVE-HF seeks to demonstrate superiority of the Revivent TC System to current guideline treatment for heart failure

SAN RAMON, Calif.--()--BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the European REVIVE-HF clinical trial of the Revivent TC™ Transcatheter Ventricular Enhancement System as co-principal investigator.


Image

BioVentrix is een particulier bedrijf op het gebied van medische hulpmiddelen dat te San Ramon, CA, in de Verenigde Staten is gevestigd.

Ons nieuws

Contact Us

© 2020 BioVentrix. Alle rechten voorbehouden. Powered by MedTech Momentum
Het Revivent TC ™ handelsmerk is een federaal geregistreerd handelsmerk dat eigendom is van BioVentrix. Elk ongeautoriseerd gebruik is uitdrukkelijk verboden.